Format
Sort by

Send to

Choose Destination

Search results

Items: 10

1.

EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression.

Lescaille G, Menashi S, Cavelier-Balloy B, Khayati F, Quemener C, Podgorniak MP, Naïmi B, Calvo F, Lebbe C, Mourah S.

BMC Cancer. 2012 Mar 23;12:115. doi: 10.1186/1471-2407-12-115.

2.

EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2.

Bougatef F, Menashi S, Khayati F, Naïmi B, Porcher R, Podgorniak MP, Millot G, Janin A, Calvo F, Lebbé C, Mourah S.

PLoS One. 2010 Aug 31;5(8):e12265. doi: 10.1371/journal.pone.0012265.

3.

Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.

Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S.

PLoS One. 2010 May 19;5(5):e10715. doi: 10.1371/journal.pone.0010715.

4.

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.

Bougatef F, Quemener C, Kellouche S, Naïmi B, Podgorniak MP, Millot G, Gabison EE, Calvo F, Dosquet C, Lebbé C, Menashi S, Mourah S.

Blood. 2009 Dec 24;114(27):5547-56. doi: 10.1182/blood-2009-04-217380. Epub 2009 Oct 16.

5.

Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia.

Mourah S, Porcher R, Lescaille G, Rousselot P, Podgorniak MP, Labarchède G, Naimi B, Medioni J, Dombret H, Calvo F.

Int J Biol Markers. 2009 Jan-Mar;24(1):22-31.

PMID:
19404919
6.

Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.

Quemener C, Gabison EE, Naïmi B, Lescaille G, Bougatef F, Podgorniak MP, Labarchède G, Lebbé C, Calvo F, Menashi S, Mourah S.

Cancer Res. 2007 Jan 1;67(1):9-15.

7.

Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate.

Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P.

Prostate. 2002 Aug 1;52(3):245-52.

PMID:
12111699
8.

A tropomyosin-2 mutation suppresses a troponin I myopathy in Drosophila.

Naimi B, Harrison A, Cummins M, Nongthomba U, Clark S, Canal I, Ferrus A, Sparrow JC.

Mol Biol Cell. 2001 May;12(5):1529-39.

9.

No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer.

Naimi B, Latil A, Berthon P, Cussenot O.

Int J Cancer. 2000 Aug 1;87(3):455-6. No abstract available.

10.

Structure of a fish (Oncorhynchus mykiss) vitellogenin gene and its evolutionary implication.

Mouchel N, Trichet V, Naimi BY, Le Pennec JP, Wolff J.

Gene. 1997 Sep 15;197(1-2):147-52.

PMID:
9332360
Items per page

Supplemental Content

Write to the Help Desk